BRAF and neoplasm: The 7.5-year OS rate of 57% in patients with BRAF-mutant tumours in the nivolumab plus ipilimumab group demonstrates the efficacy of this approach in this population and highlights the question of which might represent the optimal treatment sequencing for these patients.